読み込み中
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
前日終値
$1.47
+$0.01 · +0.68%
日中の時刻はETです。市場データは遅延する場合があります。
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
日中レンジ
現在 $1.47
52週レンジ
現在 $1.47
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
68
割安
センチメント
33
弱気
リスク
62
高リスク
モメンタム
60
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
日中レンジ
現在 $1.47
52週レンジ
現在 $1.47
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1.09億 USD | 658.9万 USD | 223.5万 USD | 519.9万 USD | — |
| 売上原価 | 1310.1万 USD | — | — | — | 458.2万 USD |
| 粗利益 | 9606.3万 USD | 658.9万 USD | 223.5万 USD | 519.9万 USD | −458.2万 USD |
| 研究開発 | 9566.7万 USD | 1.07億 USD | 9271万 USD | 9717.3万 USD | 7564.8万 USD |
| 販売・一般管理 | 2400.3万 USD | 3315.5万 USD | 3470.6万 USD | 3185.7万 USD | 1465.3万 USD |
| 営業費用 | 1.11億 USD | 1.45億 USD | 1.49億 USD | 1.39億 USD | 9030.1万 USD |
| 受取利息 | 734.6万 USD | 1300.7万 USD | 1267.7万 USD | 299万 USD | 89.8万 USD |
| 支払利息 | — | — | 54万 USD | — | 127.5万 USD |
| 減価償却費と償却費 | 1310.1万 USD | 1330.4万 USD | 1304.4万 USD | 844万 USD | 374.8万 USD |
| 営業利益 | −1504万 USD | −1.38億 USD | −1.47億 USD | −1.34億 USD | −9488.3万 USD |
| 純利益 | −958万 USD | −1.27億 USD | −1.37億 USD | −1.31億 USD | −9582.4万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$7.50
上昇余地（410.20%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI889.66万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM450.75万0.01%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF261.33万0.00%954億 USD0.05%$235+0.80%
Vanguard Russell 2000 ETFVTWO145.41万0.01%180億 USD0.06%$112.66+0.50%
iShares Micro-Cap ETFIWC56.37万0.04%13.17億 USD0.60%$183+0.11%
Vanguard Health Care ETFVHT39.35万0.00%220億 USD0.09%$319.01+1.64%
Invesco Russell 2000 Dynamic Multifactor ETFOMFS32.53万0.12%2.66億 USD0.39%$49.65+0.30%
Avantis U.S. Small Cap Equity ETFAVSC32.02万0.01%30.82億 USD0.25%$69.98+0.03%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCVanguard Health Care ETFVHTInvesco Russell 2000 Dynamic Multifactor ETFOMFSAvantis U.S. Small Cap Equity ETFAVSCAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
